This new collection of breast cancer papers shows the wide range of clinical studies and translational research published in the British Journal of Cancer. Curated by our Editor-in-Chief, Adrian Harris (University of Oxford), the studies range from the difficult decisions of treating breast cancer, how people respond to a false positive test and to recent advances in BRCA1 and BRCA2 testing. Work on the role of oestrogen receptor status and BRCA2 and new work on triple receptor negative breast cancer, the androgen receptor and long-term outcome is presented. New genotypes and predictors of response to immunotherapy, as well as early phase studies on HDAC inhibitors are described. Although, not a novel agent, the important role of biosimilars is shown, and finally research on myc and metabolism in breast cancer.